Ondansetron in the treatment of nausea and vomiting. Introduction.
Marschner
N
N
Facharzt für Innere Medizin/Hämatologie, Klinik für Tumorbiologie, Freiburg, Germany.
D000970:Antineoplastic Agents / Q000009:adverse effects; D003907:Dexamethasone / Q000627:therapeutic use; D004311:Double-Blind Method; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D015201:Meta-Analysis as Topic; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D017294:Ondansetron / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D011985:Receptors, Serotonin / Q000145:classification / Q000187:drug effects; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000970:Antineoplastic Agents; D011985:Receptors, Serotonin; D017294:Ondansetron; D003907:Dexamethasone